Home / Business and Economy / Nuwellis Surges Ahead with Outpatient Therapy and Pediatric Innovation
Nuwellis Surges Ahead with Outpatient Therapy and Pediatric Innovation
13 Nov
Summary
- 23% increase in consumables utilization and 4x rise in US console sales
- New 24-hour aqueduct circuit for hospital-based outpatient use
- First Aquadex therapy delivered in outpatient setting under new CMS code
- Advancing pediatric CRRT system Vivian with new US patent allowances
In the third quarter of 2025, Nuwellis Inc. (NASDAQ:NUWE) has seen significant progress in its business. The company reported a 23% increase in consumables utilization and a fourfold increase in US console sales sequentially from the second quarter. This growth was driven by strong performance in the heart failure and critical care categories, with year-over-year growth in circuit sales and stronger console demand.
Nuwellis has also introduced a new 24-hour aqueduct circuit for hospital-based outpatient use, providing flexibility and consistency in therapy. The company achieved a milestone with the first Aquadex therapy delivered in a hospital-based outpatient setting under a new CMS reimbursement code, demonstrating its commitment to expanding access to its innovative solutions.
